Geron Corp (GERN) is trading -10% lower at $2.19 today.

Geron Corp has been trading between a 52-week high of $2.67 and a 52-week low of $0.9899. The stock has a market cap of $827 Million.

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.

Geron Corporation (NASDAQ: GERN) Rose 59.76% From Its 52-Week Low; YTD Numbers Rose 101.64% – Here Are Some Things To Keep In Mind
Marketing Sentinel 08-05-22

Geron to Announce Second Quarter 2022 Financial Results on August 11, 2022
Business Wire 08-04-22

Geron to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference
Wallstreet:Online 08-03-22

Geron Corporation (NASDAQ: GERN): Time To Buy Over The Next Few Months
Marketing Sentinel 07-26-22

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Wallstreet:Online 07-21-22